Printer Friendly

-Norwegian Cellcura delivers prototype solution to US MGH.

NORDIC BUSINESS REPORT-June 15, 2011--Norwegian Cellcura delivers prototype solution to US MGH(C)2011 M2 COMMUNICATIONS

15 June 2011 - Norwegian biotechnology company Cellcura ASA (OSL: CELL) said today it has supplied the first prototype of a stem-cell laboratory solution for testing and assessment to the Massachusetts General Hospital (MGH) in Boston, USA.

The solution was developed in close cooperation with MGH and is designed to meet the needs of stem-cell research laboratories.

MGH signed a collaboration agreement with Cellcura's US arm in December 2010, to reflect Cellcura's engagement in the development of novel assisted reproduction therapies (ART) and stem-cell medical equipment. MGH thus aims to expand its expertise and patient-care capabilities.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Date:Jun 15, 2011
Previous Article:-Bavarian Nordic announces deals to supply smallpox vaccine.
Next Article:-Norwegian oil output declines in May 2011.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters